Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
RTW Investments
AddedFeb 13, 2024
UpdatedJun 28, 2026
RTW Investments

RTW Investments

Operating

RTW Investments, a healthcare investment firm, partners with innovative health companies.

Location
New York City, NY, US
Founded
2010
Firm
Compare
Portfolio
Employees

Investments

City Therapeutics
City Therapeutics
Series B

Total Raised

$234.5M

Rounds

2

Series A$135MOctober 2024
Basking Biosciences
Basking Biosciences

Total Raised

$89.8M

Rounds

5

Series Unknown$55MJanuary 2024
Arvinas
Arvinas
Public

Total Raised

$461.6M

Rounds

5

Post Ipo Equity$350MNovember 2023
SAB Biotherapeutics
SAB Biotherapeutics
Public

Total Raised

$186.3M

Rounds

8

Post Ipo Equity$130MOctober 2023
Beta Bionics
Beta Bionics

Total Raised

$293.5M

Rounds

8

Series D$100MAugust 2023
Series C$57MFebruary 2022
Taysha Gene Therapies
Taysha Gene Therapies
Public

Total Raised

$468M

Rounds

8

Post Ipo Equity$150MAugust 2023
Kyverna Therapeutics
Kyverna Therapeutics

Total Raised

$170M

Rounds

3

Series B$60MAugust 2023
Series B$85MJanuary 2022
2seventy bio
2seventy bio
Public

Total Raised

$315M

Rounds

4

Post Ipo Equity$170MMarch 2022
Magnolia Medical Technologies
Magnolia Medical Technologies

Total Raised

$117.3M

Rounds

9

Series Unknown$46MFebruary 2022
Roivant Sciences
Roivant Sciences
Public

Total Raised

$2.5B

Rounds

8

Post Ipo Equity$200MOctober 2021
Lycia Therapeutics
Lycia Therapeutics

Total Raised

$120M

Rounds

2

Series B$70MSeptember 2021
Inbrace
Inbrace

Total Raised

$217.6M

Rounds

7

Series D$102MSeptember 2021
Whitehawk Therapeutics
Whitehawk Therapeutics
Public

Total Raised

$250.5M

Rounds

4

Post Ipo Equity$155MAugust 2021
Neurogastrx
Neurogastrx

Total Raised

$105M

Rounds

2

Series B$60MAugust 2021
Umoja Biopharma
Umoja Biopharma

Total Raised

$263M

Rounds

3

Series B$210MJune 2021
Alcyone Lifesciences
Alcyone Lifesciences

Total Raised

$38.6M

Rounds

6

Series Unknown$23MJune 2021
NiKang Therapeutics
NiKang Therapeutics

Total Raised

$260M

Rounds

3

Series C$200MMay 2021
Series B$50MSeptember 2020
Numab
Numab

Total Raised

$122M

Rounds

3

Series C$100MMay 2021
NeoGenomics Laboratories
NeoGenomics Laboratories
Acquired

Total Raised

$350.5M

Rounds

4

Post Ipo Equity$200MMay 2021
UroGen Pharma
UroGen Pharma
Public

Total Raised

$422.1M

Rounds

7

Post Ipo Equity$75MMarch 2021
Visus Therapeutics
Visus Therapeutics

Total Raised

$56M

Rounds

2

Series A$36MMarch 2021
Artiva Biotherapeutics
Artiva Biotherapeutics

Total Raised

$198M

Rounds

2

Series B$120MFebruary 2021